Coeptis Therapeutics Holdings Inc. Common Stock (COEP)

Price$13.71

Favorite Metrics

Price vs S&P 500 (26W)-24.34%

Price vs S&P 500 (4W)11.10%

Market Capitalization$80.84M

All Metrics

Book Value / Share (Quarterly)$2.36

P/TBV (Annual)5.76x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.34

Price vs S&P 500 (YTD)-11.48%

Gross Margin (TTM)86.75%

Net Profit Margin (TTM)-800.39%

EPS (TTM)$-2.82

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-2.82

EPS (Annual)$-2.81

ROI (Annual)-86.28%

Gross Margin (Annual)86.75%

Cash / Share (Quarterly)$1.11

ROA (Last FY)-73.77%

EBITD / Share (TTM)$-2.91

ROE (5Y Avg)-753.87%

Operating Margin (TTM)-945.28%

Cash Flow / Share (Annual)$-1.50

P/B Ratio5.96x

P/B Ratio (Quarterly)5.61x

Net Income / Employee (Annual)$-2

EV / Revenue (TTM)55.33x

Net Interest Coverage (TTM)-13.74x

ROA (TTM)-77.95%

EV / EBITDA (TTM)60.82x

EPS Incl Extra (Annual)$-2.81

Current Ratio (Annual)4.16x

Quick Ratio (Quarterly)3.60x

3-Month Avg Trading Volume0.06M

52-Week Price Return38.19%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.30

P/S Ratio (Annual)59.31x

Asset Turnover (Annual)0.08x

52-Week High$21.41

EPS Excl Extra (Annual)$-2.81

26-Week Price Return-20.36%

Quick Ratio (Annual)3.60x

13-Week Price Return-6.34%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)4.16x

Enterprise Value$75.415

Asset Turnover (TTM)0.10x

Book Value / Share Growth (5Y)-16.26%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-900.71%

Cash / Share (Annual)$1.11

3-Month Return Std Dev84.30%

Net Income / Employee (TTM)$-2

ROE (Last FY)-87.87%

Net Interest Coverage (Annual)-3.81x

EPS Basic Excl Extra (Annual)$-2.81

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-2.82

ROI (TTM)-108.33%

P/S Ratio (TTM)59.31x

Revenue / Share (Annual)$0.32

Tangible BV / Share (Annual)$2.30

Price vs S&P 500 (52W)8.36%

Year-to-Date Return-8.84%

5-Day Price Return2.93%

EPS Normalized (Annual)$-2.81

ROA (5Y Avg)-220.71%

Net Profit Margin (Annual)-874.29%

Month-to-Date Return15.78%

Cash Flow / Share (TTM)$-2.69

EBITD / Share (Annual)$-2.91

Operating Margin (Annual)-945.27%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-392.09%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-2.82

P/TBV (Quarterly)5.76x

P/B Ratio (Annual)5.61x

Pretax Margin (TTM)-900.72%

Book Value / Share (Annual)$2.36

Price vs S&P 500 (13W)-7.03%

Beta0.32x

Revenue / Share (TTM)$0.25

ROE (TTM)-119.55%

52-Week Low$6.26

Analyst Recommendations

Nov 2024

Dec 2024

Jan 2025

Feb 2025

2.17

Industry Peers — Finance Services(109)

Symbol	P/E Ratio (Annual)	ROE (TTM)	Operating Margin (TTM)	Revenue Growth (5Y)	Price
COEPCoeptis Therapeutics Holdings Inc. Common Stock	—	-119.55%	-945.28%	—	$13.71
AXPAmerican Express Company	20.67x	33.49%	17.76%	15.25%	$325.76
COINCoinbase Global, Inc. Class A Common Stock	41.05x	9.44%	19.99%	41.24%	$199.82
MSTRStrategy Inc Common Stock Class A	—	-7.97%	-1140.82%	-0.15%	$148.94
STRCStrategy Inc Variable Rate Series A Perpetual Stretch Preferred Stock	—	-7.97%	-1140.82%	-0.15%	$99.06
STRDStrategy Inc 10.00% Series A Perpetual Stride Preferred Stock	—	-7.97%	-1140.82%	-0.15%	$76.11
STRFStrategy Inc 10.00% Series A Perpetual Strife Preferred Stock	—	-7.97%	-1140.82%	-0.15%	$98.83
STRKStrategy Inc 8.00% Series A Perpetual Strike Preferred Stock	—	-7.97%	-1140.82%	-0.15%	$74.75
SYFSYNCHRONY FINANCIAL	7.44x	21.09%	18.39%	0.89%	$75.17
CRCLCircle Internet Group, Inc.	126.06x	-2.62%	-2.63%	—	$107.46
SOFISoFi Technologies, Inc. Common Stock	49.78x	5.87%	-19.92%	—	$19.03

About

Coeptis Therapeutics develops cell therapy platforms for cancer patients. The company's pipeline includes SNAP-CAR, a multi-antigen CAR T technology licensed from the University of Pittsburgh, and CD38-GEAR-NK, a cell therapy candidate, along with a companion diagnostic. Coeptis collaborates with VyGen-Bio and the Karolinska Institutet on its CD38-targeted oncology programs.